According to the results of the PARADIGM and PARAGON trials, which group of patients might benefit from sacubitril/valsartan?

The group of patients that might benefit from sacubitril/valsartan, specifically indicated by the results of the PARADIGM and PARAGON trials, is women with heart failure with preserved ejection fraction (HFpEF). The PARAGON trial particularly focused on this population, demonstrating that sacubitril/valsartan can reduce the risk of cardiovascular death and hospitalization for heart failure in women, even though the benefits were more pronounced in certain subgroups.

This medication works by combining the effects of neprilysin inhibition and angiotensin receptor blockade, which help improve heart function and reduce fluid overload in patients with heart failure. The favorable outcomes for women with HFpEF highlighted in the PARAGON trial suggest that they experience significant benefits from the introduction of this therapy.

Understanding the targeted effects of sacubitril/valsartan helps emphasize the importance of gender-specific responses in medication efficacy, which the trials distinctly showed, especially relating to the unique pathophysiology of heart failure in women compared to men.